Teleflex Incorporated

Teleflex is a large diversified medical device company that happens to own the two products most associated with modern battlefield haemorrhage and vascular access. Calling it a defense supplier would overstate it considerably. It is a global medtech business of around 14,000 people, headquartered at Wayne in Pennsylvania, listed on the New York Stock Exchange as TFX, selling into hospitals and health systems worldwide. Federal and military sales are a channel within that, not a segment.

The company organises around clinical areas rather than end markets: vascular access, interventional cardiology and radiology, surgical, anaesthesia, respiratory care, urology, interventional urology and emergency medicine. Eight brands carry the portfolio. Arrow covers vascular access and cardiac care catheters. Rusch covers anaesthesia and urology. LMA covers airway management, including the supraglottic airway devices that made the brand. Deknatel is sutures and surgical products with an OEM business attached. Pilling is surgical instruments. Weck covers surgical clips and closure. UroLift is the benign prostatic hyperplasia treatment. QuikClot is haemostatics.

QuikClot is the defense-relevant one and arrived by acquisition. Teleflex bought Z-Medica in December 2020 for 500 million dollars in cash plus milestone payments, picking up the QuikClot, Combat Gauze and QuikClot Control+ brands. QuikClot Combat Gauze is a kaolin-impregnated gauze that accelerates clotting when packed into a wound, and it is standard content in military individual first aid kits across NATO and beyond. It is one of the few genuinely military-originated products in a portfolio otherwise built for operating theatres.

The other military line is intraosseous access. The EZ-IO system drives a needle into the marrow space of a bone to establish infusion access in patients whose veins have collapsed from blood loss, which is the common case in serious trauma. Teleflex sells a military-specific EZ-IO configuration, a manual needle set and the T.A.L.O.N. needle set, alongside the FAST1 sternal intraosseous infusion system. Around those sit a set of products aimed squarely at prehospital trauma care: the T-POD pelvic stabilisation device, the MAD nasal atomisation device for intranasal drug delivery, cricothyrotomy equipment, oral and nasal airways, direct laryngoscopy tools and the LMA Supreme supraglottic airway.

Teleflex is in the middle of restructuring itself. In February 2025 it announced an intent to separate into two publicly traded companies, with urology, acute care and OEM moving into a new entity and vascular access, interventional and surgical staying with the remaining company, targeted for completion in 2026. It also agreed to acquire Biotronik's vascular intervention business for around 760 million euros. Which of the two resulting companies ends up holding the emergency medicine and haemostatic lines is the question worth watching for anyone with a military supply interest.